Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners

Fineline Cube Jun 22, 2026
Company Deals

Insilico Medicine and SK Biopharmaceuticals Launch $2.5B AI Drug Discovery Collaboration Targeting Neuroimmune Diseases

Fineline Cube Jun 22, 2026
Company Deals

UCB Completes $2.2B Acquisition of Candid Therapeutics to Advance BCMA T-Cell Engager for Autoimmune Diseases

Fineline Cube Jun 18, 2026
Company Deals

Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline

Fineline Cube Jun 18, 2026
Company Deals

Xunfei Healthcare Partners with Sinar Mas Group to Deploy AI Medical Solutions Across Indonesia

Fineline Cube Jun 18, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

IASO Biotherapeutics’ Fucaso Becomes First BCMA CAR-T Therapy Approved in Singapore for Relapsed/Refractory Multiple Myeloma

Fineline Cube Jun 22, 2026
Company Drug

Sanofi’s Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings

Fineline Cube Jun 22, 2026
Company Drug

CANbridge’s Maralixibat Receives Priority Review for PFIC Treatment in China

Fineline Cube Oct 17, 2023

China-based rare disease specialist CANbridge Pharmaceuticals Inc. (HKG: 1228) has announced that a New Drug...

Company R&D

WuXi Biologics Launches WuXiUI: A Revolutionary Biotech Patent Platform

Fineline Cube Oct 17, 2023

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced the...

Company Drug

Fosun Pharma Initiates Phase III Trial for ET-26 Anesthetic in China

Fineline Cube Oct 17, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a leading healthcare conglomerate in China, has...

Company Drug

Kelun-Biotech to Present SKB264 Study Results for Metastatic Breast Cancer at ESMO

Fineline Cube Oct 16, 2023

China-based pharmaceutical innovator Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) and its subsidiary Sichuan Kelun-Biotech...

Policy / Regulatory

China’s 9th National VBP Round Sets Rules for 42 Drugs Tender

Fineline Cube Oct 16, 2023

The national drug alliance procurement office has issued a notification detailing the tendering rules for...

Company Drug

Vcanbio Receives NMPA Approval for Stem Cell Therapy VUM02 Clinical Trial

Fineline Cube Oct 16, 2023

China-based biotechnology firm Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that...

Company Deals

Nona Biosciences Partners with Ingenia for Immunological Therapeutics Development

Fineline Cube Oct 16, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142) and a biotech company...

Company Drug

SciClone Pharmaceuticals Gains FDA Nod for Thymalfasin COVID-19 Vaccine Booster Study

Fineline Cube Oct 16, 2023

SciClone Pharmaceuticals Inc. (HKG: 6600), formerly a US-based and Nasdaq-listed company, has announced that it...

Company Deals

Atom Bioscience Secures $82M Series D to Advance Gout Treatment ABP-671

Fineline Cube Oct 16, 2023

China-based Atom Bioscience, known formally as Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd, has reportedly...

Company Deals

Shanghai Pharma Health Commerce Secures $68M in Series C Funding Round

Fineline Cube Oct 16, 2023

Shanghai Pharma Health Commerce Co., Ltd, a distinguished former subsidiary of China’s pharmaceutical giant Shanghai...

Company Drug

Hainan Poly Pharm’s PL002 Accepted for FDA Review for Liver Cancer Surgery

Fineline Cube Oct 16, 2023

China-based pharmaceutical company Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that the Investigational...

Policy / Regulatory

NMPA Announces Pathway for Developing Generic Drugs Without Reference Preparation

Fineline Cube Oct 16, 2023

The National Medical Products Administration (NMPA) has issued an announcement regarding the development of generic...

Company

Novo Nordisk Reports 33% YOY Sales Increase, Boosts GLP-1 Drug Sales Forecast

Fineline Cube Oct 16, 2023

Denmark-headquartered pharmaceutical giant Novo Nordisk (NYSE: NVO) provided a financial update last week, revealing a...

Company Deals

Shandong Saito Biotech to Acquire Majority Stake in Yingu Pharmaceutical

Fineline Cube Oct 16, 2023

China-based Shandong Saito Bio-Technology Co., Ltd. (SHE: 300583) has announced plans to acquire a 60%...

Company Drug

Pfizer’s Velsipity Approved by FDA for Ulcerative Colitis Treatment

Fineline Cube Oct 16, 2023

China-based pharmaceutical company Everest Medicines (HKG: 1952) announced that its licensing partner, Pfizer Inc. (NYSE:...

Policy / Regulatory

China’s New Drug Quality Management Measures to Take Effect in 2024

Fineline Cube Oct 16, 2023

The State Administration for Market Regulation (SAMR) has released the “Drug Operation and Use Quality...

Company

Pfizer Adjusts 2023 Revenue Projections Amidst Decreased COVID-19 Solution Demand

Fineline Cube Oct 16, 2023

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has revised its projected 2023 revenues downward, reflecting a...

Policy / Regulatory

Fujian’s Fourth Round VBP Seeks Public Feedback on Drug Procurement List

Fineline Cube Oct 16, 2023

The Fujian drug and device joint procurement center has published the “Fujian Fourth Round Drug...

Company Drug

FDA Approves Pfizer’s Braftovi + Mektovi Combo for BRAF V600E Metastatic NSCLC

Fineline Cube Oct 13, 2023

The US Food and Drug Administration (FDA) has granted Pfizer (NYSE: PFE) regulatory approval for...

Policy / Regulatory

China Introduces Trial Measures for Science and Technology Ethics Review

Fineline Cube Oct 13, 2023

The National Health Commission, Ministry of Science and Technology, Ministry of Education, and eight other...

Posts pagination

1 … 480 481 482 … 686

Recent updates

  • Jenscare’s Ken-Valve TAVR System Gains Hong Kong Approval for Aortic Regurgitation Following Mainland China Launch
  • IASO Biotherapeutics’ Fucaso Becomes First BCMA CAR-T Therapy Approved in Singapore for Relapsed/Refractory Multiple Myeloma
  • Sanofi’s Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings
  • Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners
  • Roche’s Lunsumio-Polatuzumab Combination Accepted for FDA Review in Relapsed/Refractory Large B-Cell Lymphoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Jenscare’s Ken-Valve TAVR System Gains Hong Kong Approval for Aortic Regurgitation Following Mainland China Launch

Company Drug

IASO Biotherapeutics’ Fucaso Becomes First BCMA CAR-T Therapy Approved in Singapore for Relapsed/Refractory Multiple Myeloma

Company Drug

Sanofi’s Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings

Company Deals

Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.